Red Sky Partners is a team of
biotechnology industry veterans:
Geoff Cox, PhD
- Broad general management experience at CEO
and executive levels in multiple biotechnology companies, including
all aspects of biologics development and manufacturing
- Experienced Board member of public and
private companies including as Chairman and on Audit, Compensation
and Nominating and Governance committees.
- Prior CEO and Chairman of GTC
Biotherapeutics and Aronex Pharmaceuticals; EVP of operations at
- Current Director of Biota Pharmaceuticals,
QLT, Gallus BioPharmaceuticals and MassBIO
[+] Read Geoff's full
Geoff has over 35 years of pharmaceutical and biotechnology
experience in a broad range of senior management positions in
General and Operations management, as a CEO and as a member of the
board of public and private companies. Prior to
joining Red Sky Partners in 2011, Geoff was Chairman, President and
CEO of GTC Biotherapeutics, Inc. and prior to GTC he
was Chairman and CEO of Aronex Pharmaceuticals, Inc.
From 1984 to 1997 Geoff held positions of increasing
responsibility at Genzyme Corporation, becoming EVP responsible for
Operations and the Pharmaceutical, Diagnostic and Genetics business
units. Previously he was General Manager of the U.K. manufacturing
operations for Gist-Brocades.
Currently Geoff is non-executive Chairman of the Board of
Nabi Biopharmaceuticals, Chairman of the Board of MassBio, the
Massachusetts Biotechnology Council, and is a Director of Gallus
Biopharmaceuticals. He has previously served for a number of years
on the Board of the Biotechnology Industry Organization and also as
a member of their Emerging Companies Section and Healthcare Section
Governing Body Committees. Geoff received a B.Sc.(Hons) in
Biochemistry from the University of Birmingham, U.K. and a
Ph.D. in Biochemistry from the University of East Anglia, U.K.
- Lead negotiator on more than 100 licensing,
partnering and M&A life sciences deals, including managing the
selling, buying and diligence processes.
- Headed business development, legal and IP
functions at private and public biotech companies, including during
private and IPO financings.
- Previously held CBO and senior management
roles at Domantis, Dyax, Avant and Biogen, and has been a business
strategy consultant for several biotech companies.
[+] Read Pamela's full
Pamela has more than 20 years of business development and legal
experience working in private and public biotechnology companies.
Prior to founding Red Sky Partners in early 2009, she had her
own business strategy and operations consulting practice focusin on
early stage biotechnology companies. Pamela was Chief Commercial
Officer at Domantis Ltd from October 2001 until its acquisition by
GSK for $450M in Jan 2007. At Domantis, she was responsible for
business development, IP licensing, and diligence and legal
activities, including the establishment of partnerships with Abbott
and Bristol-Myers Squibb and multi-party negotiations that led to
the company’s sale to GSK.
Before joining Domantis, Pamela was SVP, Corporate Development
at Dyax Corp, where she designed and implemented the company’s
broad-based licensing program for phage display IP and technology,
in addition to the negotiation and execution of multiple corporate
and academic partnerships and management of IP and legal matters
(including for the company’s 2000 IPO). Her prior positions include
General Counsel of T Cell Sciences and Corporate Attorney for
Biogen. Pamela has a BA in Biology from Cornell University and a JD
from the University of Wisconsin.
- 30+ years operational, general management
and board leadership experience at leading biotechnology and
healthcare products companies.
- Management of global commercial businesses,
corporate development and R&D. Led Genzyme Therapeutics
business and Corporate Development through critical growth period.
Extensive financing experience, including special-purpose
- CEO, Chairman, Vice Chairman and Executive
positions with RenaMed Biologics, Dyax, Genzyme, ZymoGenetics and
- Current Chairman of the Board of Proteon
Therapeutics; past Board member of 10 private and public companies
[+] Read Greg's full
Greg has 30 years experience in the medical products and
biotechnology fields. In general management roles as CEO or senior
executive in commercial and development stage organizations, both
public and private, he has been instrumental in the successful
growth and development of several prominent companies. Greg has
been responsible for global commercial operations including new
product launches, corporate development, and research and
development. He also has extensive financing and board director
Prior to founding Red Sky partners in early 2009, Greg held
positions of Chairman and CEO of RenaMed Biologics, Vice Chairman
of Dyax Corporation, Executive Vice President of Genzyme
Corporation, Vice President of Baxter Travenol Laboratories, and
CEO of Ardais, Viagene, and ZymoGenetics. He has served on the
Board of Directors of ten public and private healthcare companies
and two non-profit organizations and presently serves as Chairman
of the Board of Proteon Therapeutics, Inc. Greg received a B.S. in
Electrical Engineering from Bradley University and an MBA from
Harvard Business School.
- Executive responsibility for assessment, due
diligence and execution of significant business transactions as
seller or buyer and led closure of numerous private and public
- Extensive experience in global product
development, approval and launch.
- Prior C-level and EVP positions at Genzyme,
Haemonetics, Cyberkinetics and BioSurface Technology.
- Current Board member and Audit committee
chair at NeuroMetrix.
[+] Read Tim's full
Tim’s 25 year career in biotechnology, cell therapy and medical
device general management includes experience as a founder of three
start-up companies as well as senior executive assignments at two
of Massachusetts’ top 20 healthcare companies. In these roles he
has had extensive line management experience with a particular
focus on business development transactions, new product development
and launch, investor relations and corporate finance.
Prior to founding Red Sky Partners in early 2009, Tim was
President and CEO of Cyberkinetics NeuroTechnology Systems, Inc.
His previous positions include EVP of Haemonetics Corporation,
President of Genzyme Tissue Repair, the cell therapy division of
Genzyme Corporation, and EVP and CFO of BioSurface Technology. Tim
serves on the Board of Directors of NeuroMetrix, Inc., a medical
device company, and the Charles River School in Dover, MA. Tim
received a B.A. in Biochemistry from Williams College and an M.B.A.
from Harvard Business School.